Company Overview of ProNAi Therapeutics, Inc.
ProNAi Therapeutics, Inc. develops and commercializes therapies that target DNA to treat patients with cancer and other complex genetic diseases. It develops nucleic acid-based DNAi technology, a gene-silencing drug that attacks cancer and prolongs survival by turning off cancer genes at their source with a small piece of DNA delivered in a fatty particle. The company’s PNT2258 is designed to treat cancers that overexpress BCL2. Its products pipeline also includes drug candidates to treat non-Hodgkin’s lymphoma, melanoma, prostate, breast, and colon cancers. ProNAi Therapeutics, Inc. was incorporated in 2003 and is based in Plymouth, Michigan.
46701 Commerce Center Drive
Michigan Life Science and Innovation Center
Plymouth, MI 48170
Founded in 2003
Key Executives for ProNAi Therapeutics, Inc.
ProNAi Therapeutics, Inc. Key Developments
Similar Private Companies By Industry
|Bioren, Inc.||United States|
|SphynKx Therapeutics LLC||United States|
|Biopolymer Innovations, LLC||United States|
|Agilvax, Inc.||United States|
|OrphageniX, Inc.||United States|
Recent Private Companies Transactions
April 17, 2014
January 10, 2014
December 20, 2013
To contact ProNAi Therapeutics, Inc., please visit www.pronai.com. Company data is provided by Capital IQ. Please use this form to report any data issues.